Literature DB >> 3422172

Prognostic significance of bone morphogenetic activity in osteosarcoma tissue.

H Yoshikawa1, K Takaoka, K Masuhara, K Ono, Y Sakamoto.   

Abstract

The bone morphogenetic activities of the primary tumors of 30 patients with osteosarcoma were assayed. This activity was demonstrated as ectopic new bone formation on implantation of freeze-dried fractions of 12 of 30 tumors into athymic nude mice. Pulmonary metastases developed in ten (83%) of the 12 patients with osteosarcomas that produced bone morphogenetic protein (BMP), and bone metastases developed in six (50%) of the patients. The mean period from diagnosis to metastasis was 4.2 months in these patients. In contrast, pulmonary metastases developed in only eight (44%) of the patients with osteosarcomas that did not produce BMP, and bone metastases developed in only two (11%) of these patients. The mean period to metastasis was 12.3 months in these patients. The incidence of metastases in the patients with osteosarcomas producing BMP was significantly higher, and the mean period to metastasis was also significantly shorter than in the other group. The five year survival rates of patients with osteosarcomas that did and did not produce BMP were 33.3% and 54.6%, respectively (P = 0.015, log-rank test). Thus the bone morphogenetic activity of primary osteosarcoma tissue seems to be closely correlated with the prognosis of the patients.

Entities:  

Mesh:

Year:  1988        PMID: 3422172     DOI: 10.1002/1097-0142(19880201)61:3<569::aid-cncr2820610324>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Sclerostin expression in skeletal sarcomas.

Authors:  Jia Shen; Carolyn A Meyers; Swati Shrestha; Arun Singh; Greg LaChaud; Vi Nguyen; Greg Asatrian; Noah Federman; Nicholas Bernthal; Fritz C Eilber; Sarah M Dry; Kang Ting; Chia Soo; Aaron W James
Journal:  Hum Pathol       Date:  2016-08-03       Impact factor: 3.466

2.  The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter.

Authors:  I Sulzbacher; P Birner; K Trieb; E Pichlbauer; S Lang
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

Review 3.  Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.

Authors:  Pawina Jiramongkolchai; Philip Owens; Charles C Hong
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

Review 4.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

Review 5.  Roles of bone morphogenetic protein signaling in osteosarcoma.

Authors:  Alan Nguyen; Michelle A Scott; Sarah M Dry; Aaron W James
Journal:  Int Orthop       Date:  2014-09-11       Impact factor: 3.075

6.  Point-counter-point debate: the association between recombinant human bone morphogenetic protein utilization and complications in spine surgery.

Authors:  Kris Siemionow; Eric Sundberg; Marcin Tyrakowski; Sreeharsha V Nandyala; Kern Singh
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

Review 7.  Bone morphogenetic protein signaling in musculoskeletal cancer.

Authors:  Myrto Bami; Andreas F Mavrogenis; Andrea Angelini; Mandy Milonaki; Evanthia Mitsiokapa; Dimitrios Stamoulis; Panayotis N Soucacos
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-04       Impact factor: 4.553

8.  NELL-1 expression in tumors of cartilage.

Authors:  Jia Shen; Gregory LaChaud; Swati Shrestha; Greg Asatrian; Xinli Zhang; Sarah M Dry; Chia Soo; Kang Ting; Aaron W James
Journal:  J Orthop       Date:  2015-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.